Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
If you love creative paracord projects, mind-blowing weaves, and unique survival gear, you need to follow me! Join the Weavers of Eternity community for expert tutorials, fun challenges, and must-know ...
On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...
You must be logged in to rate. Click any rating to login.
On July 22, 2025, Replimune revealed that the FDA had issued a Complete Response Letter (CRL) for its Biologics License Application for RP1, a novel immunotherapy aimed at treating advanced melanoma.
Donald Trump's executive order changing 401(k)s: What to know Lucasfilm and Disney settle with actor Gina Carano following her firing from 'The Mandalorian' Windows 10’s escape hatch widens again, but ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
LOS ANGELES, July 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or ...
Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...
Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback